Nymox Pharmaceutical Corp (NYMXF) Common Stock USD NPV
$0.01
(16.67%)
- Add to watchlist
- This stock can be held in a
$0.01
(16.67%)
Deal for just £11.95 per trade in a
Fund and Share Account
$0.01
(16.67%)
Business summary
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NYMOZARFEX, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company also has a patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications. It also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Its products also include NicAlert and TobacAlert. NicAlert is a simple test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample. TobacAlert is a home test that provides a quick, accurate, on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke.
Contact details
Important dates
General stock information
- Short code:
- NYMXF
- ISIN:
- BSP733981026
- Market cap:
- $5.61 million
- Shares in issue:
- 93.45 million
- Sector:
- Biotechnology
- Exchange:
- Off Exchange
- Country:
- Bahamas
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.